Suggestion to the document
Listen to audio
Get a link from a document elementMemorandum of understanding
Suggestion to the documentListen to audioGet a link from a document elementbetween the Government of the Republic of Uzbekistan and the Government of the Republic of Serbia
Suggestion to the documentListen to audioGet a link from a document elementOn Cooperation in the Pharmaceutical and Biotechnological Sectors
Suggestion to the documentListen to audioGet a link from a document elementSuggestion to the documentListen to audioGet a link from a document elementThe Government of the Republic of Uzbekistan and the Government of the Republic of Serbia (hereinafter referred to as the “Participants”),
Suggestion to the documentListen to audioGet a link from a document elementReaffirming the friendly relations and expanding economic cooperation between the two States,
Suggestion to the documentListen to audioGet a link from a document elementRecognizing the strategic importance of pharmaceutical production, biotechnology and life sciences for public health, innovation and sustainable economic development,
Suggestion to the documentListen to audioGet a link from a document elementTaking into account international standards governing the development, manufacture and regulation of medicines, including the principles of Good Manufacturing Practices (GMP), Good Clinical Practices (GCP) and Good Laboratory Practices (GLP),
Suggestion to the documentListen to audioGet a link from a document elementAcknowledging the growing potential for cooperation between the pharmaceutical industries, regulatory authorities and research institutions of both countries,
Suggestion to the documentListen to audioGet a link from a document elementDesiring to promote joint research, development and production of pharmaceuticals, biotechnology products and medical devices,
Suggestion to the documentListen to audioGet a link from a document elementHave reached the following understanding:
Suggestion to the documentListen to audioGet a link from a document elementArticle 1
Purpose and Scope
Purpose and Scope
Suggestion to the documentListen to audioGet a link from a document element1. The purpose of this Memorandum is to establish a comprehensive framework for cooperation between the Participants in the fields of pharmaceuticals, biotechnology and medical technologies.
Suggestion to the documentListen to audioGet a link from a document element2. Cooperation under this Memorandum will aim to:
Suggestion to the documentListen to audioGet a link from a document elementpromote joint research, development and innovation in pharmaceutical and biotechnological fields;
Suggestion to the documentListen to audioGet a link from a document elementstrengthen the production capacities of pharmaceutical industries in both countries;
Suggestion to the documentListen to audioGet a link from a document elementencourage investment and industrial partnerships in pharmaceutical manufacturing;
Suggestion to the documentListen to audioGet a link from a document elementfacilitate technology transfer and exchange of scientific knowledge;
Suggestion to the documentListen to audioGet a link from a document elementenhance regulatory cooperation and alignment with internationally recognized quality and safety standards.
Suggestion to the documentListen to audioGet a link from a document element3. This Memorandum will apply to cooperation between competent governmental authorities, regulatory agencies, scientific institutions, universities and private-sector entities operating in the pharmaceutical and biotechnology sectors.
Suggestion to the documentListen to audioGet a link from a document element4. Implementation of cooperation under this Memorandum will be carried out in accordance with the national legislation of the Participants and applicable international obligations as well as in the case of the Republic of Serbia, obligations arising from the European Union accession process.
Suggestion to the documentListen to audioGet a link from a document elementArticle 2
Priority Areas of Cooperation
Priority Areas of Cooperation
Suggestion to the documentListen to audioGet a link from a document element1. The Participants will promote cooperation in the following priority areas:
Suggestion to the documentListen to audioGet a link from a document elementa) research and development of pharmaceutical products, vaccines and biotechnology-based therapies;
Suggestion to the documentListen to audioGet a link from a document elementb) development and production of generic medicines, biosimilars and biological products;
Suggestion to the documentListen to audioGet a link from a document elementc) research and production of medical devices and diagnostic technologies;
Suggestion to the documentListen to audioGet a link from a document elementd) pharmaceutical raw materials and active pharmaceutical ingredients (APIs);
Suggestion to the documentListen to audioGet a link from a document elemente) biotechnology applications in medicine, public health and pharmaceutical manufacturing.
Suggestion to the documentListen to audioGet a link from a document element2. The Participants will encourage collaboration between universities, research institutes, biotechnology companies and pharmaceutical manufacturers to promote scientific and technological innovation.
Suggestion to the documentListen to audioGet a link from a document element3. The Participants may also cooperate in emerging fields of biotechnology, including genomic medicine, personalized medicine and advanced therapeutic technologies.
Suggestion to the documentListen to audioGet a link from a document elementArticle 3
Regulatory Cooperation and Quality Assurance
Regulatory Cooperation and Quality Assurance
Suggestion to the documentListen to audioGet a link from a document element1. The Participants will promote cooperation between their competent regulatory authorities responsible for the authorization, supervision and control of pharmaceutical products and medical devices.
Suggestion to the documentListen to audioGet a link from a document element2. Such cooperation may include:
Suggestion to the documentListen to audioGet a link from a document elementexchange of regulatory information and best practices concerning pharmaceutical legislation;
Suggestion to the documentListen to audioGet a link from a document elementcooperation in drug registration procedures;
Suggestion to the documentListen to audioGet a link from a document elementexchange of data on safety monitoring and pharmacovigilance systems;
Suggestion to the documentListen to audioGet a link from a document elementcooperation on laboratory testing and quality control mechanisms.
Suggestion to the documentListen to audioGet a link from a document element3. The Participants will encourage alignment of regulatory standards with internationally recognized guidelines, including:
Suggestion to the documentListen to audioGet a link from a document elementGood Manufacturing Practices (GMP);
Suggestion to the documentListen to audioGet a link from a document elementGood Clinical Practices (GCP);
Suggestion to the documentListen to audioGet a link from a document elementGood Laboratory Practices (GLP);
Suggestion to the documentListen to audioGet a link from a document elementrelevant guidelines of the World Health Organization and other international bodies.
Suggestion to the documentListen to audioGet a link from a document element4. The Participants may consider establishing mechanisms for cooperation in:
Suggestion to the documentListen to audioGet a link from a document elementinspection of pharmaceutical manufacturing facilities;
Suggestion to the documentListen to audioGet a link from a document elementexchange of information on certification procedures;
Suggestion to the documentListen to audioGet a link from a document elementmutual assistance in regulatory capacity building.
Suggestion to the documentListen to audioGet a link from a document elementArticle 4
Clinical Trials and Biomedical Research
Clinical Trials and Biomedical Research
Suggestion to the documentListen to audioGet a link from a document element1. The Participants will encourage cooperation in biomedical research and clinical trials related to pharmaceutical and biotechnology products.
Suggestion to the documentListen to audioGet a link from a document element2. Such cooperation may include:
Suggestion to the documentListen to audioGet a link from a document elementjoint research projects on vaccines, biologics and innovative therapies;
Suggestion to the documentListen to audioGet a link from a document elementdevelopment of biosimilar medicines;
Suggestion to the documentListen to audioGet a link from a document elementcollaboration in epidemiological and biomedical research.
Suggestion to the documentListen to audioGet a link from a document element3. Clinical trials conducted under this Memorandum will comply with:
Suggestion to the documentListen to audioGet a link from a document elementthe national legislation of the Participants;
Suggestion to the documentListen to audioGet a link from a document elementinternationally recognized ethical standards;
Suggestion to the documentListen to audioGet a link from a document elementapplicable international guidelines on clinical research.
Suggestion to the documentListen to audioGet a link from a document element4. The Participants will encourage collaboration between hospitals, research institutes and pharmaceutical companies to facilitate the development and evaluation of new pharmaceutical products.
Suggestion to the documentListen to audioGet a link from a document elementArticle 5
Industrial Cooperation and Technology Transfer
Industrial Cooperation and Technology Transfer
Suggestion to the documentListen to audioGet a link from a document element1. The Participants will promote cooperation between pharmaceutical and biotechnology companies of the two countries with the aim of strengthening industrial production capacities.
Suggestion to the documentListen to audioGet a link from a document element2. Such cooperation may include:
Suggestion to the documentListen to audioGet a link from a document elementestablishment of joint ventures for the manufacturing of pharmaceutical and biotechnology products;
Suggestion to the documentListen to audioGet a link from a document elementconstruction or modernization of pharmaceutical production facilities;
Suggestion to the documentListen to audioGet a link from a document elementtransfer of technologies and know-how related to pharmaceutical manufacturing.
Suggestion to the documentListen to audioGet a link from a document element3. The Participants will encourage cooperation in the production of:
Suggestion to the documentListen to audioGet a link from a document elementgeneric medicines;
Suggestion to the documentListen to audioGet a link from a document elementvaccines and biological products;
Suggestion to the documentListen to audioGet a link from a document elementbiosimilars;
Suggestion to the documentListen to audioGet a link from a document elementmedical diagnostic equipment and biotechnology products.
Suggestion to the documentListen to audioGet a link from a document element4. The Participants will facilitate industrial partnerships through appropriate mechanisms, including:
Suggestion to the documentListen to audioGet a link from a document elementinvestment cooperation;
Suggestion to the documentListen to audioGet a link from a document elementpublic-private partnerships;
Suggestion to the documentListen to audioGet a link from a document elementcollaboration between research institutions and industrial enterprises.
Suggestion to the documentListen to audioGet a link from a document elementCooperation in technology transfer will respect the protection of intellectual property rights in accordance with the national legislation of the Participants and relevant international agreements.
Suggestion to the documentListen to audioGet a link from a document elementArticle 6
Education, Training and Capacity Building
Education, Training and Capacity Building
Suggestion to the documentListen to audioGet a link from a document elementThe Participants will promote cooperation in education and professional training in pharmaceutical sciences and biotechnology, including:
Suggestion to the documentListen to audioGet a link from a document elementexchange of researchers, scientists and experts;
Suggestion to the documentListen to audioGet a link from a document elementjoint academic programmes and training courses;
Suggestion to the documentListen to audioGet a link from a document elementinternships and professional development programmes for regulatory specialists and laboratory personnel.
Suggestion to the documentListen to audioGet a link from a document elementArticle 7
Financial Arrangements
Financial Arrangements
Suggestion to the documentListen to audioGet a link from a document element1. Implementation of cooperation activities under this Memorandum will be carried out in accordance with the national legislation of the Participants and subject to the availability of financial resources.
Suggestion to the documentListen to audioGet a link from a document element2. The Participants may encourage participation of international organizations, development banks and other financial institutions in projects carried out under this Memorandum.
Suggestion to the documentListen to audioGet a link from a document elementArticle 8
Status
Status
Suggestion to the documentListen to audioGet a link from a document element1. This Memorandum records the intentions of the Participants only. It is not an international treaty and does not create any rights or obligations under international or national law.
Suggestion to the documentListen to audioGet a link from a document element2. This Memorandum does not affect the rights and obligations of the Republic of Uzbekistan and the Republic of Serbia under other international agreements.
Suggestion to the documentListen to audioGet a link from a document elementArticle 9
Settlement of Disputes
Settlement of Disputes
Suggestion to the documentListen to audioGet a link from a document elementAny dispute concerning the interpretation or implementation of this Memorandum will be resolved through consultations and negotiations between the Participants through diplomatic channels.
Suggestion to the documentListen to audioGet a link from a document elementArticle 10
Amendments
Amendments
Suggestion to the documentListen to audioGet a link from a document elementThis Memorandum may be amended by mutual written consent of the Participants. Amendments will come into effect in accordance with the procedure established in Article 11 of this Memorandum.
Suggestion to the documentListen to audioGet a link from a document elementArticle 11
Effect, Duration and Discontinuance
Effect, Duration and Discontinuance
Suggestion to the documentListen to audioGet a link from a document element1. This Memorandum will come into effect on the date of its signature.
Suggestion to the documentListen to audioGet a link from a document element2. This Memorandum will remain in effect for five (5) years and will be automatically extended for successive five-year periods unless one of the Participants notifies the other Participant in writing of its intention to discontinue this Memorandum at least six months before its expiration.
Suggestion to the documentListen to audioGet a link from a document element3. The discontinuance of this Memorandum will not affect the implementation of ongoing projects initiated under this Memorandum.
Suggestion to the documentListen to audioGet a link from a document elementDone at Belgrade, on 8 September 2026, in two originals, in the Uzbek, Serbian and English languages, all texts being equally authentic. In case of divergence of interpretation, the English text will prevail.
Suggestion to the documentListen to audioGet a link from a document element(signatures)